Stock Events

Stock Events

Alvotech

$0.24

18

-$0.01-4% Monday 19:39

Statistics

Day High

0.28

Day Low

0.25

52W High

2.74

52W Low

0.16

Volume

3,220

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

6MayExpected

Q2 2024

Q3 2024

Q4 2024

Q2 2025

Q3 2025

Q4 2025

Next

-0.47

-0.27

-0.06

0.14

Expected EPS

-0.046998

Actual EPS

N/A

Financials

-84.79%Profit Margin

Unprofitable

2019

2020

2021

2022

2023

2024

546.94MRevenue

-463.73MNet Income

Analyst Ratings

5Average Price Target

The highest estimate is 6.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.

Buy

50%

Hold

0%

Sell

50%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALVOW. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Amgen is a biotechnology company focused on developing novel therapeutics, including biosimilars, which directly competes with Alvotech's biosimilar product portfolio.

Pfizer is a global pharmaceutical company with a strong presence in the biosimilars market, making it a direct competitor to Alvotech in the biosimilar space.

Biogen has a focus on biologics and has ventured into the biosimilars market, positioning it as a competitor to Alvotech.

Novartis, through its generics division Sandoz, is a leading company in the biosimilars market, competing with Alvotech in developing and marketing biosimilar products.

Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, including biosimilars, competing with Alvotech in the biosimilar pharmaceuticals market.

Merck & Co., known as MSD outside the United States and Canada, has made strides in biosimilars, making it a competitor to Alvotech.

AbbVie has a growing interest in biosimilars, particularly with its Humira biosimilar, directly competing with Alvotech's biosimilar development efforts.

Roche, through its Genentech unit, is involved in the development of biosimilars, competing with Alvotech in the biotechnology and biosimilars market.

Sanofi is expanding its presence in the biosimilars market, making it a competitor to Alvotech in the development and commercialization of biosimilar products.

AstraZeneca is involved in biopharmaceuticals and has shown interest in biosimilars, positioning it as a competitor to Alvotech in the biosimilar and biologics market.

About

Alvotech Holdings SA, through its subsidiaries, develops and manufactures biosimilars for global markets. The company is based in Iceland.

Show more...

CEO

Mr. Vilhelm Robert Wessman

Employees

1012

Country

Luxembourg

ISIN

LU2458333858

Listings

0 Comments

Share your thoughts

FAQ

What is Alvotech stock price today?▼

The current price of ALVOW is $0.24 USD — it has decreased by -4% in the past 24 hours. Watch Alvotech stock price performance more closely on the chart.

What is Alvotech stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Alvotech stocks are traded under the ticker ALVOW.

Is Alvotech stock price growing?▼

ALVOW stock has risen by +12.94% compared to the previous week, the month change is a -17.21% fall, over the last year Alvotech has showed a -81.39% decrease.

What is Alvotech revenue for the last year?▼

Alvotech revenue for the last year amounts to 546.94M USD.

What is Alvotech net income for the last year?▼

ALVOW net income for the last year is -463.73M USD.

How many employees does Alvotech have?▼

As of May 06, 2026, the company has 1,012 employees.

In which sector is Alvotech located?▼

Alvotech operates in the Health & Wellness sector.

When did Alvotech complete a stock split?▼

Alvotech has not had any recent stock splits.

Where is Alvotech headquartered?▼

Alvotech is headquartered in Luxembourg, Luxembourg.